TY - JOUR
T1 - A third SARS-CoV-2 spike vaccination improves neutralization of variants-of-concern
AU - Brinkkemper, Mitch
AU - Brouwer, Philip J. M.
AU - Maisonnasse, Pauline
AU - Grobben, Marloes
AU - Caniels, Tom G.
AU - Poniman, Meliawati
AU - Burger, Judith A.
AU - Bontjer, Ilja
AU - Oomen, Melissa
AU - Bouhuijs, Joey H.
AU - van der Linden, Cynthia A.
AU - Villaudy, Julien
AU - van der Velden, Yme U.
AU - Sliepen, Kwinten
AU - van Gils, Marit J.
AU - le Grand, Roger
AU - Sanders, Rogier W.
N1 - Funding Information: We thank P. Bieniasz for kindly sharing the pHIV-1NL43ΔENV-NanoLuc and SARS-CoV-2-SΔ19 plasmids. We thank Dietmar Katinger and Philipp Mundsperger for providing the squalene emulsion and MPLA liposome adjuvants. This work was supported by a Netherlands Organization for Scientific Research (NWO) Vici grant (to R.W.S.); by the Bill & Melinda Gates Foundation through the Collaboration for AIDS Vaccine Discovery (CAVD) grants OPP1111923, OPP1132237, and INV-002022 (to R.W.S.) by the Fondation Dormeur, Vaduz (to R.W.S. and to M.J.v.G.) and Health Holland PPS-allowance LSHM20040 (to M.J.v.G.). M.J.v.G. is a recipient of an AMC Fellowship from Amsterdam UMC and a COVID-19 grant from the Amsterdam Institute for Infection and Immunity. R.W.S and M.J.v.G. are recipients of support from the University of Amsterdam Proof of Concept fund (contract no. 200421) as managed by Innovation Exchange Amsterdam (IXA). The Infectious Disease Models and Innovative Therapies (IDMIT) research infrastructure is supported by the “Programme Investissements d’Avenir”, managed by the ANR under reference ANR-11-INBS-0008. The Fondation Bettencourt Schueller and the Region Ile-de-France contributed to the implementation of IDMIT’s facilities and imaging technologies. The NHP study received financial support from REACTing, the National Research Agency (ANR; AM-CoV-Path), and the European Infrastructure TRANSVAC2 (730964). The funders had no role in study design, data collection, data analysis, data interpretation, or data reporting. Publisher Copyright: © 2021, The Author(s).
PY - 2021/12/1
Y1 - 2021/12/1
N2 - The emergence of SARS-CoV-2 variants that are more resistant to antibody-mediated neutralization pose a new hurdle in combating the COVID-19 pandemic. Although vaccines based on the original Wuhan sequence have been shown to be effective at preventing COVID-19, their efficacy is likely to be decreased against more neutralization-resistant variants-of-concern (VOC), in particular, the Beta variant originating in South Africa. We assessed, in mice, rabbits, and non-human primates, whether a third vaccination with experimental Wuhan-based Spike vaccines could alleviate this problem. Our data show that a third immunization improves neutralizing antibody titers against the variants-of-concern, Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2). After three vaccinations, the level of neutralization against Beta was similar to the level of neutralization against the original strain after two vaccinations, suggesting that simply providing a third immunization could nullify the reduced activity of current vaccines against VOC.
AB - The emergence of SARS-CoV-2 variants that are more resistant to antibody-mediated neutralization pose a new hurdle in combating the COVID-19 pandemic. Although vaccines based on the original Wuhan sequence have been shown to be effective at preventing COVID-19, their efficacy is likely to be decreased against more neutralization-resistant variants-of-concern (VOC), in particular, the Beta variant originating in South Africa. We assessed, in mice, rabbits, and non-human primates, whether a third vaccination with experimental Wuhan-based Spike vaccines could alleviate this problem. Our data show that a third immunization improves neutralizing antibody titers against the variants-of-concern, Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2). After three vaccinations, the level of neutralization against Beta was similar to the level of neutralization against the original strain after two vaccinations, suggesting that simply providing a third immunization could nullify the reduced activity of current vaccines against VOC.
UR - http://www.scopus.com/inward/record.url?scp=85120911874&partnerID=8YFLogxK
U2 - https://doi.org/10.1038/s41541-021-00411-7
DO - https://doi.org/10.1038/s41541-021-00411-7
M3 - Article
C2 - 34862406
SN - 1476-0584
VL - 6
JO - npj Vaccines
JF - npj Vaccines
IS - 1
M1 - 146
ER -